Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 17/20 | 0.95 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL14645374 | 1.00 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14645377 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL6270347 | 0.98 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL18898 | 0.98 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL579001 | 0.95 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL167772 | 0.95 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1115700 | 0.95 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL19614558 | 0.95 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4646147 | 0.95 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4284352 | 0.95 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2731591-B1 | LIPOSOMES CO-ENCAPSULATING A BISPHOSPHONATE AND AN AMPHIPATHIC AGENT | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2020-06-17 | — | — | EP | disclosed |
| US-10617672-B2 | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C | LIPOMEDIX PHARMACEUTICALS LTD. (IL) | 2020-04-14 | — | — | US | disclosed |
| US-20180296529-A1 | LIPOSOME COMPOSITION CO-ENCAPSULATING DOXORUBICIN AND A PRODRUG OF MITOMYCIN C | LIPOMEDIX PHARMACEUTICALS LTD. (IL) | 2018-10-18 | — | — | US | disclosed |
| US-10085940-B2 | Liposomes co-encapsulating a bisphosphonate and an amphipathic agent | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-10-02 | — | — | US | disclosed |
| EP-3362099-A1 | LIPOSOME COMPOSITION CO-ENCAPSULATING DOXORUBICIN AND A PRODRUG OF MITOMYCIN C | Lipomedix Pharmaceuticals Ltd. (IL) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066667-A1 | LIPOSOME COMPOSITION CO-ENCAPSULATING DOXORUBICIN AND A PRODRUG OF MITOMYCIN C | LIPOMEDIX PHARMACEUTICALS LTD. (IL) | 2017-04-20 | — | — | WO | disclosed |
| US-20140328899-A1 | LIPOSOMES CO-ENCAPSULATING A BISPHOSPHONATE AND AN AMPHIPATHIC AGENT | SHAARE ZEDEK MEDICAL CENTER (IL) | 2014-11-06 | — | — | US | disclosed |
| EP-2731591-A2 | LIPOSOMES CO-ENCAPSULATING A BISPHOSPHONATE AND AN AMPHIPATHIC AGENT | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013008240-A2 | LIPOSOMES CO-ENCAPSULATING A BISPHOSPHONATE AND AN AMPHIPATHIC AGENT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OFJERUSALEM LTD. (IL) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296529-A1 | LIPOSOME COMPOSITION CO-ENCAPSULATING DOXORUBICIN AND A PRODRUG OF MITOMYCIN C | MTDH, LIPA, PHOSPHO1 | FDPS 804/4885PDE3A 1226/4885LMNA 30/4885 |
| US-10617672-B2 | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C | MTDH, LIPA, PHOSPHO1 | FDPS 804/4885PDE3A 1226/4885LMNA 30/4885 |
| US-10085940-B2 | Liposomes co-encapsulating a bisphosphonate and an amphipathic agent | FOLR1, FOLR2, CD4 | FDPS 343/4885PDE3A 4496/4885LMNA 685/4885 |
| US-20140328899-A1 | LIPOSOMES CO-ENCAPSULATING A BISPHOSPHONATE AND AN AMPHIPATHIC AGENT | FOLR1, FOLR2, CD4 | FDPS 343/4885PDE3A 4496/4885LMNA 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.